Agilent SureSelect cancer tumor-specific assays

Agilent SureSelect cancer tumor-specific assays offer genomic profiling of solid tumors with next-generation sequencing (NGS) panels for lung, colon, pancreas, bladder, and kidney. The panels are comprised of DNA modules of approximately 50 genes each for sequencing on Illumina^® MiSeq™ and MiniSeq instruments, enabling tumor genomic profiling at a lower cost. Agilent demonstrates the target coverage and distribution uniformity of the assays, their consistent detection of key somatic variant classes, de novo gene fusion detection from just one gene partner, and variant detection from cell-free DNA (cfDNA) samples.